Fetal hemoglobin induction during decitabine treatment of elderly high-risk MDS and AML patients: A potential dynamic biomarker for outcome

被引：0
|
作者：
Stomper, J. [1 ,2 ]
Ihorst, G. [2 ,3 ]
Suciu, S. [4 ]
Sander, P. N. [1 ,2 ]
Becker, H. [1 ,2 ]
Wijermans, P. W. [5 ]
Bisse, E. [2 ,6 ]
Claus, R. [1 ,2 ,7 ]
Luebbert, M. [1 ,2 ,8 ]
机构：
[1] Univ Freiburg, Fac Med, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany
[2] Univ Freiburg, Med Ctr, Freiburg, Germany
[3] Univ Freiburg, Fac Med, Clin Trials Unit, Freiburg, Germany
[4] EORTC Headquarters, Brussels, Belgium
[5] Haga Hosp, Dept Hematol, The Hague, Netherlands
[6] Univ Freiburg, Fac Med, Inst Clin Chem & Lab Med, Freiburg, Germany
[7] Augsburg Med Ctr, Dept Internal Med 2, Hematol Oncol, Augsburg, Germany
[8] German Canc Res Consortium DKTK, Freiburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V90
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [41] Elevated Pre-Treatment Fetal Hemoglobin Predicts Better Outcome in MDS/AML Patients Receiving 5-Aza-2'-Deoxycytidine (DAC)
    Claus, Rainer
    Ihorst, Gabriele
    Sander, Philipp
    Bogatyreva, Ljudmila
    Becker, Heiko
    Wijermans, Pierre W.
    Suciu, Stefan
    Bisse, Emmanuel
    Lubbert, Michael
    [J]. BLOOD, 2016, 128 (22)
  • [42] Azatidine Treatment in Very Elderly Patients Diagnosed with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
    Gutierrez, Javier
    Morales, Elena
    Gonzalez, Matilde
    Herrada, Juan
    [J]. BLOOD, 2015, 126 (23)
  • [43] PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Daver, N.
    Kantarjian, H.
    Garcia-Manero, G.
    Jabbour, E.
    Borthakur, G.
    Pierce, S.
    Vaughan, K.
    Vaughan, K.
    Ning, J.
    Gonzalez, G.
    Pemmarjau, N.
    Kadia, T.
    Konopleva, M.
    Andreeff, M.
    DiNardo, C.
    Cortes, J.
    Ward, R.
    Craig, A.
    Ravandi, F.
    [J]. HAEMATOLOGICA, 2016, 101 : 187 - 188
  • [44] Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis
    Grunwald, Victoria V.
    Hentrich, Marcus
    Schiel, Xaver
    Dufour, Annika
    Schneider, Stephanie
    Neusser, Michaela
    Subklewe, Marion
    Fiegl, Michael
    Hiddemann, Wolfgang
    Spiekermann, Karsten
    Rothenberg-Thurley, Maja
    Metzeler, Klaus H.
    [J]. BLOOD ADVANCES, 2019, 3 (18) : 2696 - 2699
  • [45] Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
    Anne Sophie Kubasch
    Freya Schulze
    Aristoteles Giagounidis
    Katharina S. Götze
    Jan Krönke
    Katja Sockel
    Jan Moritz Middeke
    Fatiha Chermat
    Silke Gloaguen
    Martin Puttrich
    Carmen Weigt
    Doreen William
    Pierre Fenaux
    Richard F. Schlenk
    Christian Thiede
    Sebastian Stasik
    Anna Mies
    Lionel Adès
    Uta Oelschlägel
    Uwe Platzbecker
    [J]. Leukemia, 2020, 34 : 1182 - 1186
  • [46] Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
    Kubasch, Anne Sophie
    Schulze, Freya
    Giagounidis, Aristoteles
    Goetze, Katharina S.
    Kroenke, Jan
    Sockel, Katja
    Middeke, Jan Moritz
    Chermat, Fatiha
    Gloaguen, Silke
    Puttrich, Martin
    Weigt, Carmen
    William, Doreen
    Fenaux, Pierre
    Schlenk, Richard F.
    Thiede, Christian
    Stasik, Sebastian
    Mies, Anna
    Ades, Lionel
    Oelschlaegel, Uta
    Platzbecker, Uwe
    [J]. LEUKEMIA, 2020, 34 (04) : 1182 - 1186
  • [47] Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS
    Joshua F. Zeidner
    Hanna A. Knaus
    Amer M. Zeidan
    Amanda L. Blackford
    Raul Montiel-Esparza
    Hubert Hackl
    Gabrielle T. Prince
    Lukasz P. Gondek
    Gabriel Ghiaur
    Margaret M. Showel
    Amy E. DeZern
    Keith W. Pratz
    B. Douglas Smith
    Mark J. Levis
    Steven Gore
    Catherine C. Coombs
    Matthew C. Foster
    Howard Streicher
    Judith E. Karp
    Leo Luznik
    Ivana Gojo
    [J]. Leukemia, 2020, 34 : 1563 - 1576
  • [48] Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS
    Zeidner, Joshua F.
    Knaus, Hanna A.
    Zeidan, Amer M.
    Blackford, Amanda L.
    Montiel-Esparza, Raul
    Hackl, Hubert
    Prince, Gabrielle T.
    Gondek, Lukasz P.
    Ghiaur, Gabriel
    Showel, Margaret M.
    DeZern, Amy E.
    Pratz, Keith W.
    Smith, B. Douglas
    Levis, Mark J.
    Gore, Steven
    Coombs, Catherine C.
    Foster, Matthew C.
    Streicher, Howard
    Karp, Judith E.
    Luznik, Leo
    Gojo, Ivana
    [J]. LEUKEMIA, 2020, 34 (06) : 1563 - 1576
  • [49] Causes of death in patients (pts) with acute myelogenous lukemia (AML) and high-risk myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC).
    Mattiuzzi, GN
    Alvarado, G
    Alvarez, R
    Pierce, S
    Cortes, J
    Kantarjian, H
    Giles, F
    Faderl, S
    Estey, E
    [J]. BLOOD, 2003, 102 (11) : 878A - 878A
  • [50] Breast Cancer Treatment in High-Risk Elderly Patients
    Bano, Razia
    Khan, Iqbal Amina
    Zaidi, Akif Abbas
    Zaidi, Asif Syed Adil
    Khan, Huma Majeed
    Chaudhary, Muhammad Zulqarnain
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : 32 - 32
12345